Kaplan-Meier analysis of persistence among patients switching from a previous GLP-1 receptor agonist to dulaglutide once weekly, exenatide twice daily or once weekly, or liraglutide once daily. Patients were switched from dulaglutide (5.0%), exenatide twice daily (28.1%), exenatide once weekly (17.4%), or liraglutide (49.5%). Data are from a retrospective analysis of a German prescription database using data from 1 February 2014 to 31 March 2017. Reprinted with permission from Otto et al. (57). BID, twice daily; QW, once weekly.